Published in Am J Transplant on November 28, 2011
Intention to treat outcome of T1 hepatocellular carcinoma with the "wait and not ablate" approach until meeting T2 criteria for liver transplant listing. Liver Transpl (2016) 1.49
Long-term outcomes following aggressive management of recurrent hepatocellular carcinoma after upfront liver resection. World J Surg (2012) 0.85
Transplant benefit for patients with hepatocellular carcinoma. World J Gastroenterol (2013) 0.81
Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther (2012) 0.77
Halofuginone for fibrosis, regeneration and cancer in the gastrointestinal tract. World J Gastroenterol (2014) 0.75
Radiofrequency ablation versus reresection in treating recurrent hepatocellular carcinoma: a meta-analysis. Medicine (Baltimore) (2014) 0.75
Surgery and Hepatocellular Carcinoma. Liver Cancer (2016) 0.75
Living Donor Liver Transplantation Outcomes for Hepatocellular Carcinoma Beyond Milan or UCSF Criteria. Indian J Surg (2014) 0.75
Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) (2017) 0.75
Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol (2017) 0.75
Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit. Transl Gastroenterol Hepatol (2017) 0.75